Vertex continues to capitalize on its leadership in cystic fibrosis (CF) treatments, where its blockbuster drug Trikafta is ...

Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our ...

Vertex Pharmaceuticals sees early success with Journavx painkiller, potential revenue growth from drug and gene therapy.

We recently published a list of 10 Best Long Term Growth Stocks to Buy According to Billionaires. In this article, we are ...

Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...

We feel now is a pretty good time to analyse Vertex, Inc.'s (NASDAQ:VERX) business as it appears the company may be on the cusp of a considerable accomplishment. Vertex, Inc., together with its ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial.

Wells Fargo analyst Mohit Bansal maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target ...

Vertex Pharmaceuticals has discontinued the development of VX-264, a type 1 diabetes (T1D) cell therapy delivered via an implantable device, after clinical trial data showed the treatment did not ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

We feel now is a pretty good time to analyse Vertex, Inc.'s (NASDAQ:VERX) business as it appears the company may be on the cusp of a considerable accomplishment. Vertex, Inc., together with its ...